FILE:BSX/BSX-8K-20080109171130.txt.gz
EVENTS:	Entry into a Material Definitive Agreement	Financial Statements and Exhibits
TEXT:
ITEM: Entry into a Material Definitive Agreement
ITEM: Financial Statements and Exhibits
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
 
 
 
 
On January 3, 2008, we completed the sale of the controlling interests in our auditory business and drug pump development program to former principals and shareholders of Advanced Bionics Corporation.  The sale coincides with the closing of the amended merger agreement with Advanced Bionics previously announced on August 9, 2007.
As part of a new schedule of consolidated, fixed earnout payments, we paid former Advanced Bionics shareholders $650 million.  A final payment of $500 million will be paid in March 2009.  The former Advanced Bionics principals and shareholders have paid us $150 million for our controlling interests in the auditory business and drug pump development program.
The forms of material agreements related to this transaction were previously filed on a Form 8-K dated August 9, 2007.  A form of Amendment No. 2 to Agreement and Plan of Merger, Amendment No. 1 to Cochlear Implant Business Purchase and Sale Agreement and the press release issued on January 4, 2008 are filed as Exhibit 10.1, Exhibit 10.2 and Exhibit 99.1 hereto.
 
 
 
 
 
 
 
 
 
 
- 2 -
 
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 3 -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
- 4 -

EXHIBIT 10.1 ------------ -------------------- FORM OF AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER -------------------- among BOSTON SCIENTIFIC CORPORATION, BOSTON SCIENTIFIC SCIMED, INC., ADVANCED BIONICS CORPORATION, THE BIONICS TRUST and JEFFREY D. GOLDBERG AND CARLA WOODS (COLLECTIVELY IN THEIR CAPACITY AS THE STOCKHOLDERS' REPRESENTATIVE) Dated as of August 9, 2007
TABLE OF CONTENTS Page ARTICLE I. AMENDMENT 1 SECTION 1.01 Amendment to Article I.................1 SECTION 1.02 Amendment to Article II................2 SECTION 1.03 Amendment to Article III...............4 SECTION 1.04 Amendment to Article IV................4 SECTION 1.05 Amendment to Article V.................4 SECTION 1.06 Amendment to Article VI................5 SECTION 1.07 Amendment to Article VII...............5 SECTION 1.08 Amendment to Article VIII..............5 SECTION 1.09 Amendment to Exhibit H.................5 ARTICLE II. GENERAL PROVISIONS 6 SECTION 2.01 No Further Amendment...................6 SECTION 2.02 Counterparts...........................6 i
This AMENDMENT NO. 2 TO THE AGREEMENT AND PLAN OF MERGER (this "Amendment 2"), dated as of August 9, 2007, is entered into by and among BOSTON SCIENTIFIC CORPORATION, a Delaware corporation ("Parent"), BOSTON SCIENTIFIC SCIMED, INC., (formerly known as Scimed Life Systems, Inc.) a Minnesota corporation and a wholly owned subsidiary of Parent ("Scimed"), ADVANCED BIONICS CORPORATION, a Delaware corporation and a wholly owned subsidiary of Scimed (the "Company"), the BIONICS TRUST (the "Trust") and CARLA WOODS and JEFFREY D. GOLDBERG (such persons acting together by majority vote, and any successor persons acting together by majority vote, solely in their capacity as Stockholders' Representative under the Merger Agreement being the "Stockholders' Representative"). This Amendment 2 will become effective as of the Closing (as defined in the Amendment Agreement) if the Amendment Agreement has not been terminated prior to such time; provided that in no event will this Amendment 2 become effective until Scimed has paid the First Earn Out Payment. WHEREAS, Parent, Scimed, Claude Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Scimed, the Company, the Trust and the Stockholders' Representative entered into that certain Agreement and Plan of Merger dated as of May 28, 2004 (the "Original Merger Agreement") and entered into Amendment No. 1 to the Original Merger Agreement on August 9, 2007 ("Amendment 1") which became effective as of September __, 2007. Capitalized terms used herein but not defined herein have the meaning ascribed to such terms in the Original Merger Agreement. References herein to a specific Article, Section, Schedule or Exhibit will refer, respectively, to Articles, Sections, Schedules or Exhibits of the Original Merger Agreement unless otherwise specified. The Original Merger Agreement as amended by Amendment 1 is referred to herein as the "Merger Agreement"). WHEREAS, this Amendment 2 is being executed and delivered pursuant to Section 2.01(b) of that certain Amendment Agreement dated as of August 9, 2007 (the "Amendment Agreement") among Parent, Scimed, the Company, the Trust and the Stockholders' Representative to further amend the Merger Agreement. NOW, THEREFORE, in consideration of the premises and the mutual agreements and covenants hereinafter set forth, and intending to be legally bound, the Parties hereby agree as follows: ARTICLE I. AMENDMENT SECTION 1.01 Amendment to Article I. Article I will be amended to add the following definitions, which will be placed in Article I in alphabetical order: "Amendment 2" means Amendment No. 2 to this Agreement among the parties to this Agreement (other than the Purchaser) dated as of August 9, 2007 and effective as of the Closing Date (as that term is defined in the Amendment Agreement).
"Amendment 2 Closing" means the "Closing" (as that term is defined in the Amendment Agreement). "Amendment Agreement" means that certain Amendment Agreement dated as of August 9, 2007 among the parties to this Agreement (other than the Purchaser). SECTION 1.02 Amendment to Article II. (a) Amendment to Sections 2.01, 2.02, 2.03, 2.04, 2.05, 2.06, 2.07, 2.08. 2.09, 2.10 and 2.13. The parties hereto acknowledge and agree that as of the Amendment 2 Closing no further actions are required to be performed pursuant to Sections 2.01, 2.02, 2.03, 2.04, 2.05, 2.06, 2.07, 2.08, 2.09, 2.10 and 2.13. (b) Amendment to Section 2.11. The following new Sections 2.11(j) and (k) will be added at the end of Section 2.11: (j) At the Amendment 2 Closing, Scimed will pay, or cause to be paid, to the Bionics Trust, the following: (i) the First Earn Out Payment (as defined in the Amendment Agreement); and (ii) the Earn Out Obligation (as defined in the Amendment Agreement). (k) The payment by Scimed to the Bionics Trust of the First Earn Out Payment and the delivery of the Earn Out Obligation described in Section 2.11(j) will be in full satisfaction of all payments that would have otherwise become due and payable under this Section 2.11, including any payments that would have become due during or with respect to the 2007 fiscal year. After the payment of the First Earn Out Payment and the delivery of the Earn Out Obligation described above (and the payment of the amount due thereunder), no further Earn Out Payments will be due and payable by Scimed to the Bionics Trust pursuant to this Section 2.11. (c) Amendment to Section 2.12. Section 2.12 will be amended as follows: (i) Section 2.12(c) will be deleted in its entirety and replaced with the following: (c) In connection with this Agreement (as it may be amended from time to time) and any instrument, agreement or document relating hereto or thereto, and in exercising or failing to exercise all or any of the powers conferred upon the
Stockholders' Representative hereunder (including executing and delivering any amendment hereto), the Stockholders' Representative will incur no responsibility whatsoever to any Stockholder, Earn Out Recipient, or Bionics Trust by reason of any error in judgment or other act or omission performed or omitted hereunder or in connection with this Agreement (as it may be amended from time to time) or any such other agreement, instrument or document, excepting only responsibility for any act or failure to act which represents gross negligence or willful misconduct. Each Earn Out Recipient and Bionics Trust will indemnify the Stockholders' Representative against all Losses arising out of or in connection with any claim, investigation, challenge, action or proceeding or in connection with any appeal thereof, relating to the acts or omissions of the Stockholders' Representative arising under this Agreement (as it may be amended from time to time). The Stockholders' Representative will, at the expense of the Earn Out Recipients and Bionics Trust, be entitled to engage such counsel, experts and other agents and consultants as he or she will deem necessary in connection with exercising his or her powers and performing his or her function hereunder. (ii) The following will be added to the end of Section 2.12: The parties hereto acknowledge and agree that except for the amendment to Section 2.12(c) as provided for in Amendment 2, this Section 2.12 will survive the Amendment 2 Closing and will not be modified by the transactions contemplated by Amendment 2. (d) Amendment to Section 2.14. Section 2.14 will be deleted in its entirety and replaced with the following: Withholding Rights. Each of Parent, Scimed and the Surviving Corporation (the "BSC Withholding Parties") will be entitled to deduct and withhold from any amounts otherwise payable pursuant to this Agreement (including payments on or with respect to the Earn Out Obligation) such amount as they are required to deduct and withhold with respect to the making of such payment under applicable Tax Law. To the extent that amounts are so withheld and properly paid to the appropriate Tax authority, such amounts will be treated for purposes of this Agreement as having been paid to the holder of the securities or rights in respect of which such deduction and withholding was made. The Stockholders' Representative and the Bionics Trust will provide reasonable assistance to the BSC Withholding Parties in connection with the determination of amounts required to be deducted and withheld and compliance with related information reporting requirements. If the BSC Withholding Parties intend to deduct and withhold from an amount payable pursuant to this Agreement (including payments on or with respect to the Earn Out Obligation) in a manner that materially differs from the manner in which the BSC Withholding Parties deducted and withheld amounts from the Earn Out Payment made on or about March
9, 2007, the BSC Withholding Parties will promptly provide the Bionics Trust with a letter from counsel to the BSC Withholding Parties (i) describing in reasonable detail any change in facts or circumstances necessitating such change in the manner of such deduction and withholding or (ii) providing a reasoned analysis of the change in applicable Law or change in understanding or interpretation of applicable Law necessitating such change in the manner of deduction and withholding. SECTION 1.03 Amendment to Article III. The following will be added to the end of Article III: The parties hereto acknowledge and agree that this Article III will not survive the Amendment 2 Closing, and that from and after the Amendment 2 Closing, this Article III will be of no further force or effect for any purpose whatsoever. SECTION 1.04 Amendment to Article IV. The following will be added to the end of Article IV: The parties hereto acknowledge and agree that this Article IV will not survive the Amendment 2 Closing, and that from and after the Amendment 2 Closing, this Article IV will be of no further force or effect for any purpose whatsoever. SECTION 1.05 Amendment to Article V. (a) Amendment to Sections 5.01, 5.04(a), 5.04(b), 5.04(c), 5.04(d), 5.04(e), 5.04(f), 5.04(g), 5.09 and 5.10. The parties hereto acknowledge and agree that from and after the Amendment 2 Closing, Sections 5.01, 5.04(a), 5.04(b), 5.04(c), 5.04(d), 5.04(e), 5.04(f), 5.04(g), 5.09, and 5.10 will be of no further force or effect. (b) Amendment to Sections 5.02, 5.04(h) and 5.04(i). The parties hereto acknowledge and agree that Sections 5.02, 5.04(h), and 5.04(i), will survive the Amendment 2 Closing and will not be modified by the transactions contemplated by Amendment 2. (c) Amendment to Section 5.04(j). The following will be added to the end of Section 5.04(j): The parties hereto acknowledge and agree that this Section 5.04(j) will survive the Amendment 2 Closing and will not be modified by the transactions contemplated by Amendment 2 for actions occurring before the Amendment 2 Closing. The Parties acknowledge and agree that this Section 5.04(j) will be of no further force or effect for actions taken after the Amendment 2 Closing.
(d) Amendment to Sections 5.05, 5.07, 5.08 and 5.11. The parties hereto acknowledge and agree that as of the Amendment 2 Closing no further actions are required to be performed pursuant to Sections 5.05, 5.07, 5.08, and 5.11. (e) Amendment to Section 5.06. Section 5.06 shall be deleted in its entirety and replaced with the following: Promptly following the Amendment 2 Closing, the Company will pay to the Bionics Trust $850,000.00 in immediately available funds as a return of funds previously withheld pursuant to this Section 5.06. SECTION 1.06 Amendment to Article VI. (a) Amendment to Sections 6.01, 6.02, 6.03 and 6.04. The parties hereto acknowledge and agree that from and after the Amendment 2 Closing, Sections 6.01, 6.02, 6.03 and 6.04 will be of no further force or effect. SECTION 1.07 Amendment to Article VII. (a) Amendment to Section 7.01. The following new Section (c) will be added to the end of Section 7.01: Notwithstanding anything contained in this Section 7.01 to the contrary, the representations and warranties of the Company, Parent, Scimed and Purchaser contained in this Agreement will not survive the Amendment 2 Closing and will be of no further force or effect after the Amendment 2 Closing. (b) Amendment to Sections 7.02, 7.03, 7.04, 7.05, 7.06, 7.07 and 7.08. The parties hereto acknowledge and agree that, from and after the Amendment 2 Closing, Sections 7.02, 7.03, 7.04, 7.05, 7.06, 7.07 and 7.08 will be of no further force or effect. SECTION 1.08 Amendment to Article VIII. A new Section 8.16 will be added to the end of Article VIII as follows: Section 8.16 Survival. The parties hereto acknowledge and agree that this Article VIII will survive the Amendment 2 Closing and will not be modified by the transactions contemplated by Amendment 2 and that Sections 8.10 and 8.11 will be of no further force and effect. SECTION 1.09 Amendment to Exhibit H. Exhibit H will be deleted in its entirety and replaced with the following: o Waiver of, or any Amendment or change in, the right to receive any amount under the Earn Out Obligation where the amount in question exceeds $50 million.
ARTICLE II. GENERAL PROVISIONS SECTION 2.01 No Further Amendment. Except as expressly amended hereby, all of the provisions of the Merger Agreement will be and remain in full force and effect. SECTION 2.02 Counterparts. This Amendment 2 may be executed and delivered (including by facsimile transmission) in one or more counterparts, and by the different Parties in separate counterparts, each of which when executed will be deemed to be an original but all of which taken together will constitute one and the same agreement. [SIGNATURE PAGE FOLLOWS]
IN WITNESS WHEREOF, each of the Parties have executed or caused this Amendment 2 to be duly executed as of the date first written above by such party or by any officer of such party thereunto duly authorized, as applicable. BOSTON SCIENTIFIC CORPORATION By: _______________________________ Name: Title: BOSTON SCIENTIFIC SCIMED, INC. By: _______________________________ Name: Title: ADVANCED BIONICS CORPORATION By: _______________________________ Name: Title: THE STOCKHOLDERS' REPRESENTATIVE By:________________________________ Name: Carla Woods By:________________________________ Name: Jeffrey D. Goldberg BIONICS TRUST By:________________________________ Name: Carla Woods By:________________________________ Name: Jeffrey D. Goldberg

EXHIBIT 10.2 ------------ FORM OF AMENDMENT NO. 1 TO COCHLEAR IMPLANT BUSINESS PURCHASE AND SALE AGREEMENT This AMENDMENT NO. 1 to the COCHLEAR IMPLANT BUSINESS PURCHASE AND SALE AGREEMENT (this "Amendment"), dated as of January 3, 2008, is entered into by and among BOSTON SCIENTIFIC CORPORATION, a Delaware corporation ("Parent"), BOSTON SCIENTIFIC SCIMED, INC. (formerly known as Scimed Life Systems, Inc.), a Minnesota corporation and a wholly owned subsidiary of Parent ("Scimed"), BOSTON SCIENTIFIC NEUROMODULATION CORPORATION (formerly known as Advanced Bionics Corporation), a Delaware corporation and a wholly owned subsidiary of Scimed (the "Seller"), ADVANCED BIONICS HOLDING CORPORATION, a California corporation (the "Purchaser"), and ADVANCED BIONICS, LLC (formerly known as Auditory Systems, LLC), a Delaware limited liability company (the "Company"). All capitalized terms used herein but not defined herein have the meaning ascribed to such terms in the Agreement (as hereinafter defined), and, except as otherwise provided below, references herein to a specific Section or Schedule will refer, respectively, to the corresponding Section or Schedule of the Agreement. WHEREAS, Parent, Scimed, the Seller, the Purchaser and the Company have entered into the COCHLEAR IMPLANT BUSINESS PURCHASE AND SALE AGREEMENT (the "Agreement"), dated as of August 9, 2007; and WHEREAS, the parties hereto desire to amend the Agreement on the terms and subject to the conditions set forth herein. NOW, THEREFORE, in consideration of the premises and the mutual agreements and covenants in the Agreement and hereinafter set forth, and intending to be legally bound, the parties hereto hereby agree as follows: 1. Change of Certain Names. From and after the effective date of this Amendment, all references to the Company in the Agreement will be deemed to refer to "Advanced Bionics, LLC" rather than "Auditory Systems, LLC." From and after the effective date of this Amendment, all references to the Seller in the Agreement will be deemed to refer to "Boston Scientific Neuromodulation Corporation" rather than "Advanced Bionics Corporation." 2. Acknowledgement. The parties hereto hereby acknowledge and agree that the forms of the Ancillary Agreements attached to the Agreement will be revised to reflect the change of the name of the (a) Seller to "Boston Scientific Neuromodulation Corporation" and (b) Company to "Advanced Bionics, LLC." 3. Amendment of Section 2.02(a)(iii). Section 2.02(a)(iii) is hereby deleted in its entirety and replaced with the following: "all the Receivables, including (for the avoidance of doubt) a Receivable in the amount of approximately $25,414,884.27 held by the Seller from Advanced Bionics Sarl (France)."
4. Amendment of Section 3.02(e). Section 3.02(e) is hereby deleted in its entirety and replaced with the following: "On the Closing Date, the Seller will pay to the Company $6,700,000 by wire transfer of immediately available funds to a bank account designated by the Company." 5. Amendment of Section 3.05(a)(i). Section 3.05(a)(i) is hereby deleted in its entirety and replaced with the following: "(i) a certificate evidencing 880 Class A Units issued by the Company in the name of the Purchaser and an instrument duly executed by the Seller, which assigns, transfers and delivers such Class A Units to the Purchaser, in form and substance satisfactory to the Purchaser;" 6. Amendment of Section 3.05(a)(ix). The words ", and comparable certificates, if available in the relevant jurisdiction, of good standing from the jurisdictions applicable to the Parent Designated Affiliates" contained in Section 3.05(a)(ix) are hereby deleted in their entirety. 7. Amendment of Section 3.05(a)(x). Section 3.05(a)(x) is hereby deleted in its entirety and replaced with the following: "valid instruments of conveyance duly executed by the Seller which evidence the assignment, transfer and delivery to the Company of the securities of the Transferred Subsidiaries, in form and substance satisfactory to the Purchaser;" 8. Amendment of Section 7.07(a). The words "The Seller will change its name within 10 Business Days after the Closing Date, and within three months after the date on which such name change occurs, the Seller will cease to use the name "Advanced Bionics," "Bionics" and "Bionic" in any public communications" contained in the first sentence of Section 7.07(a) are hereby deleted in their entirety and replaced with the following: "The Seller will cease to use the names `Advanced Bionics,' `Bionics' and `Bionic' in any public communications by February 16, 2008;" 9. Amendment of Section 8.02(a). The second sentence of Section 8.02(a) is hereby deleted in its entirety and replaced with the following: "On January 18, 2008, the Seller will pay to the recipients under the Cash Bonus Plan (the "Cash Bonus Plan Recipients") an aggregate amount equal to $2,189,660.00 (which represents $5.38 per Cash Bonus Plan Unit)." 10. Amendment of Section 8.02. The following new Section 8.02(c) is hereby added after Section 8.02(b): "The Seller will pay to the Company an amount of cash equal to 50% of the French social Taxes paid by Advanced Bionics Sarl (France) to the appropriate Governmental Authority in respect of the portion of the First Earn Out Payment (as defined in the Amendment Agreement) and the Earn Out Obligation (as 2
defined in the Amendment Agreement) that is paid to former French option holders of the Seller who are or were employees of Advanced Bionics Sarl (France), to the extent that Advanced Bionics Sarl (France) determines that it is obligated by applicable Law to pay such Taxes; provided that the Seller will not be required to pay to either the Company or such Governmental Authority any portion of any penalties, interest or legal fees incurred or levied in respect of such Taxes. The Seller will make such payment within five Business Days of its receipt from the Company of evidence reasonably satisfactory to the Seller that such payment has been made to such Governmental Authority." 11. Amendment of Schedule 1.01(a). The following names are hereby added to Schedule 1.01(a): - ----------------- ----------------------------- ---------------- --------------- Country Mark Name Application # Registration # - ----------------- ----------------------------- ---------------- --------------- Argentina HARMONY 2,769,019 Not available - ----------------- ----------------------------- ---------------- --------------- United States HealingJourney 77/149,636 Not available - ----------------- ----------------------------- ---------------- --------------- United States Imagine the Possibilities 78/135,900 2,713,593 - ----------------- ----------------------------- ---------------- --------------- 12. Amendment of Schedule 1.01(c). The lease in respect of the address "28460 Avenue Stanford, Suite 150, Valencia, CA 91355" is hereby deleted from Schedule 1.01(c) in its entirety. 13. Amendment of Schedule 1.01(e)(i). Schedule 1.01(e)(i) is hereby deleted in its entirety and replaced by Schedule 1.01(e)(i) attached hereto. 14. Amendment of Schedule 1.01(e)(ii). Schedule 1.01(e)(ii) is hereby deleted in its entirety and replaced by Schedule 1.01(e)(ii) attached hereto. 15. Amendment of Schedule 1.01(f). (a) The following are hereby added as items 4, 5, 6 and 7 to the section entitled "Export" of Schedule 1.01(f): "4. License No. CT-10425 issued by the United States Department of Treasury, Cuban Assets Control Regulation, on August 31, 2007 5. Commodity Classification issued by the United States Department of Commerce, BIS for the Harmony Cochlear Implant System on August 31, 2007 6. Commodity Classification issued by the United States Department of Commerce, BIS for the Cochlear Implant System on February 26, 2005 7. License No. IA-9831 for Iran filed with the United States Office of Foreign Assets Control, on December 7, 2007 (as supplemented)" 3
(b) The Section of Schedule 1.01(f) entitled "Reimbursement" and the phrase "Medicare and Medicaid Provider Numbers" thereunder are hereby deleted in their entirety. 16. Amendment of Schedule 1.01(g). Schedule 1.01(g) is hereby deleted and replaced in its entirety by Schedule 1.01(g) attached hereto. 17. Amendment of Schedule 1.01(h). (a) The contracts referred to in Attachment 1.01(h)-A attached hereto are hereby added to the section of Schedule 1.01(h) entitled "Auditory Agreements." (b) The contracts referred to in Attachment 1.01(h)-B attached hereto are hereby added to the section of Schedule 1.01(h) entitled "Auditory Consulting Agreements." (c) The following contracts referred to in the section of Schedule 1.01(h) entitled "Auditory Agreements" are hereby deleted in their entirety: Name Effective Date Type of Agreement - ---------------------------------- --------------------- ----------------------- Parter Sterilization Services 1/8/2007 Supplier Agreement - ---------------------------------- --------------------- ----------------------- Quallion, LLC. 6/1/2004 Supplier Agreement - ---------------------------------- --------------------- ----------------------- Air Liquide Industrial LP. 6/15/2007 Supplier Agreement - ---------------------------------- --------------------- ----------------------- 18. Amendment of Schedule 2.02(a)(xi). The time period "10/1/2006-10/1/2007" listed under the column "Policy Period" in Schedule 2.02(a)(xi) is hereby deleted in its entirety and replaced by "10/1/2006-1/31/2008." 19. Amendment of Schedule 2.02(a)(xviii). Section 3 of Schedule 2.02(a)(xviii) and the corresponding attachment to Schedule 2.02(a)(xviii) is hereby deleted in its entirety. 20. Amendment of Schedule 2.04. Schedule 2.04 is hereby deleted in its entirety and replaced by Schedule 2.04 attached hereto. 21. Other Provisions of the Agreement. Except as set forth in this Amendment, all terms and conditions of the Agreement shall remain in full force and effect. 22. Governing Law. This Amendment and all disputes or controversies arising out of or relating to this Amendment or the transactions contemplated hereby will be governed by, and construed in accordance with, the laws of the State of New York. Except as provided in Sections 2.06(b), 3.02(c) and 3.03(b) of the Agreement, all actions and proceedings arising out of or relating to this Amendment will be heard and determined exclusively in any New York federal court sitting in the Borough of Manhattan of The City of New York. In the event that jurisdiction is not available in any federal court sitting in the Borough of Manhattan of The City of New York, the parties agree that all such actions and proceedings will be heard in the state courts of Delaware located in the City of Wilmington. The parties hereby (a) submit to 4
the exclusive jurisdiction of any federal court sitting in the Borough of Manhattan of The City of New York for the purpose of any Action arising out of or relating to this Amendment brought by any party (subject to the preceding sentence), and (b) irrevocably waive, and agree not to assert by way of motion, defense, or otherwise, in any such Action, any Claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the Action is brought in an inconvenient forum, that the venue of the Action is improper, or that this Amendment or the transactions contemplated by this Amendment may not be enforced in or by any of the above-named courts. 23. Counterparts. This Amendment may be executed and delivered (including by facsimile transmission) in one or more counterparts, and by the different parties in separate counterparts, each of which when executed will be deemed to be an original but all of which taken together will constitute one and the same agreement. [SIGNATURE PAGE FOLLOWS] 5
IN WITNESS WHEREOF, each of the parties hereto has executed or caused this Amendment to be duly executed as of the date first written above by their respective officers thereunto duly authorized. BOSTON SCIENTIFIC CORPORATION By: __________________________________________ Name: Lawrence J. Knopf Title: Senior Vice President, Deputy General Counsel and Assistant Secretary BOSTON SCIENTIFIC SCIMED, INC. By: __________________________________________ Name: Lawrence J. Knopf Title: Assistant Secretary BOSTON SCIENTIFIC NEUROMODULATION CORPORATION By: __________________________________________ Name: Lawrence J. Knopf Title: Vice President-Legal and Secretary ADVANCED BIONICS HOLDING CORPORATION By: __________________________________________ Name: Title: ADVANCED BIONICS, LLC By: BOSTON SCIENTIFIC NEUROMODULATION CORPORATION, as sole member By: __________________________________________ Name: Lawrence J. Knopf Title: Vice President-Legal and Secretary

 
Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
Company retains ownership of Pain Management business
PRNewswire-FirstCall
NATICK, Mass.
(NYSE:BSX)
NATICK, Mass., Jan. 4 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has completed the sale of the controlling interests in its auditory business and drug pump development program to former principals and shareholders of Advanced Bionics. Boston Scientific acquired Advanced Bionics in 2004. The sale coincides with the closing of the amended merger agreement with Advanced Bionics announced on August 9, 2007.
As part of a new schedule of consolidated, fixed earnout payments, Boston Scientific has paid former Advanced Bionics shareholders $650 million. A final payment of $500 million will be paid in March 2009. The former Advanced Bionics principals and shareholders have paid Boston Scientific $150 million for the controlling interests in the auditory business and drug pump development program.
Under the amended merger agreement, Boston Scientific obtains sole management control of the Pain Management business, including the emerging indications program. The Pain Management business includes spinal cord stimulation technologies, as well as emerging technologies such as a variety of applications of the bion microstimulator. The Pain Management business and emerging indications program will operate as Boston Scientific Neuromodulation under the leadership of Michael Onuscheck, currently head of the Pain Management business. The business will continue to be headquartered in Valencia, California.
As part of the transactions, the parties have agreed to dismiss currently pending litigation between Boston Scientific and former Advanced Bionics shareholders.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.
 
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our divestiture of non-strategic assets, our restructuring initiatives, our operational strategy, our financial performance and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
 
 
SOURCE:   Boston Scientific Corporation
CONTACT:   Media Relations, Paul Donovan, +1-508-650-8541 (office), +1-508-667-5165 (mobile), or Investor Relations, Dan Brennan, +1-508-650-8538 (office), +1-617-459-2703 (mobile), both of Boston Scientific Corporation


